| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.24 | 2e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.21 | 4e-05 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | 0.23 | 7e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.24 | 0.0001 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.24 | 0.0002 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.001 |